Trulieve Cannabis Corp.

CNSX:TRUL Stock Report

Market Cap: CA$1.3b

Trulieve Cannabis Valuation

Is TRUL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRUL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TRUL (CA$6.95) is trading below our estimate of fair value (CA$25)

Significantly Below Fair Value: TRUL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRUL?

Key metric: As TRUL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TRUL. This is calculated by dividing TRUL's market cap by their current revenue.
What is TRUL's PS Ratio?
PS Ratio0.8x
SalesUS$1.17b
Market CapUS$923.50m

Price to Sales Ratio vs Peers

How does TRUL's PS Ratio compare to its peers?

The above table shows the PS ratio for TRUL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.4x
CURA Curaleaf Holdings
0.8x11.6%CA$1.6b
CRON Cronos Group
6.7x8.7%CA$1.1b
GTII Green Thumb Industries
1.7x9.5%CA$2.7b
VRNO Verano Holdings
0.5x3.0%CA$678.0m
TRUL Trulieve Cannabis
0.8x3.6%CA$1.3b

Price-To-Sales vs Peers: TRUL is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.4x).

Price to Sales Ratio vs Industry

How does TRUL's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.1x4.0%US$51.54m
IAN iAnthus Capital Holdings
0.1xn/aUS$23.22m
TIUM.U Cansortium
0.2xn/aUS$22.56m
RWB Red White & Bloom Brands
0.2xn/aUS$13.09m
TRUL 0.8xIndustry Avg. 0.8xNo. of Companies27PS012345+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TRUL is expensive based on its Price-To-Sales Ratio (0.8x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is TRUL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRUL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: TRUL is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TRUL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$6.95
CA$23.26
+234.7%
18.8%CA$32.57CA$17.04n/a9
Dec ’25CA$8.47
CA$23.31
+175.2%
16.7%CA$32.12CA$19.09n/a9
Nov ’25CA$17.22
CA$26.07
+51.4%
34.9%CA$46.03CA$15.98n/a9
Oct ’25CA$16.13
CA$25.16
+56.0%
33.1%CA$44.67CA$18.58n/a10
Sep ’25CA$11.72
CA$25.48
+117.4%
31.0%CA$44.55CA$18.84n/a11
Aug ’25CA$13.83
CA$25.71
+85.9%
27.6%CA$41.75CA$18.99n/a11
Jul ’25CA$12.73
CA$26.14
+105.3%
27.1%CA$41.29CA$18.96n/a10
Jun ’25CA$13.32
CA$25.48
+91.3%
27.8%CA$41.27CA$18.95n/a11
May ’25CA$16.51
CA$22.61
+37.0%
24.9%CA$35.06CA$15.23n/a11
Apr ’25CA$16.95
CA$20.74
+22.4%
31.2%CA$34.96CA$8.89n/a11
Mar ’25CA$14.17
CA$20.74
+46.4%
31.2%CA$34.96CA$8.89n/a11
Feb ’25CA$14.22
CA$17.67
+24.2%
40.6%CA$32.83CA$8.72n/a11
Jan ’25CA$6.85
CA$16.77
+144.8%
42.0%CA$32.83CA$8.91n/a10
Dec ’24CA$7.48
CA$16.77
+124.2%
42.0%CA$32.83CA$8.91CA$8.4710
Nov ’24CA$6.13
CA$17.30
+182.2%
43.3%CA$32.94CA$8.02CA$17.2210
Oct ’24CA$8.25
CA$17.12
+107.6%
43.8%CA$33.29CA$7.86CA$16.1310
Sep ’24CA$8.00
CA$16.39
+104.8%
45.4%CA$32.95CA$7.87CA$11.7211
Aug ’24CA$5.53
CA$17.16
+210.4%
47.2%CA$32.98CA$7.97CA$13.8311
Jul ’24CA$5.20
CA$17.05
+227.9%
47.3%CA$32.32CA$6.79CA$12.7311
Jun ’24CA$5.52
CA$21.78
+294.5%
53.2%CA$50.08CA$6.93CA$13.3212
May ’24CA$7.60
CA$25.29
+232.7%
44.9%CA$50.44CA$9.11CA$16.5112
Apr ’24CA$7.48
CA$25.70
+243.6%
40.6%CA$51.07CA$9.99CA$16.9514
Mar ’24CA$8.49
CA$35.47
+317.8%
30.0%CA$52.63CA$18.16CA$14.1714
Feb ’24CA$8.90
CA$35.40
+297.7%
29.5%CA$50.95CA$17.95CA$14.2214
Jan ’24CA$10.26
CA$36.54
+256.1%
28.4%CA$51.92CA$18.25CA$6.8514
Dec ’23CA$18.50
CA$36.06
+94.9%
28.6%CA$52.23CA$17.97CA$7.4814

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trulieve Cannabis Corp. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Kenric TygheATB Capital Markets